|Awarded On||August 24, 2018|
|Title||Targeting BRAF- and RAS-Mutant Cancers by Small Molecule-Induced Proteolysis of ERK1/2|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Kevin Dalby|
|Cancer Sites||Colorectal, Lung and Bronchus, Melanoma|
Melanoma is a deadly form of skin cancer killing approximately ten thousand Americans per year, with a disproportionate number residing in Texas. Diagnoses are expected to increase by 26% over the next 16 years, and will have a proportionally greater impact on young adults as well as on African-American and Hispanic populations in Texas. There is an urgent need for novel drugs for treating patients with drug-resistant melanomas. The focus of this proposal is to address this unmet medical need and to develop an entirely novel therapeutic modality with a triple mechanism of action against an enzyme called ERK which is critical for melanoma. These mechanisms are – 1) inhibiting ERK activation,...